Biotechnology firms utilizing generative machine learning models for target identification are transitioning their lead candidates into Phase II clinical trials. While time-to-candidate selection was reduced by up to 50%, clinical attrition rates remain governed by biological complexity.
Regulatory Scrutiny
Regulatory agencies are standardizing evaluation metrics for algorithmic candidate optimization, focusing on off-target toxicity profiles and pharmacokinetic predictability.